Considerations for drug trials in hypertrophic cardiomyopathy
Abstract Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies has been recognized for decades.
John P. Farrant+17 more
wiley +1 more source
Incidence and prognosis of obstruction of the left ventricular outflow tract in Liverpool (1960-91): a study of 313 patients. [PDF]
Denise Kitchiner+5 more
openalex +1 more source
Ethnical variations in the incidence of congenital heart defects in Gorgan, Northern Iran: A single-center study [PDF]
Background: Congenital heart disease (CHD) is the most common congenital anomaly in newborns. This study was performed to determine the live birth incidence of CHD by ethnicity and sex in Gorgan, Northern Iran.
Golalipour, M.J.+4 more
core
A phenomap of TTR amyloidosis to aid diagnostic screening
Abstract Cardiac amyloidosis due to transthyretin (ATTR) remains an underdiagnosed cause of cardiomyopathy. As awareness of the disease grows and referrals for ATTR increase, clinicians are likely to encounter more atypical forms of the condition in clinical practice.
Alexios S. Antonopoulos+4 more
wiley +1 more source
Obstruction of right ventricular outflow tract by solitary ovarian metastasis.
D N Griffith, Anne Myers
openalex +1 more source
Subaortic stenosis caused by an unusual fibrous blood-filled cyst of the left ventricle with outflow tract obstruction associated with a ventricular septal defect. [PDF]
S Nakae, Atsushi Kurata, Akira Ishihara
openalex +1 more source
Sacubitril/valsartan preserves regional cardiac function following myocardial infarction in rats
Parts of the figure were drawn by using pictures from Servier Medical Art. Servier Medical Art by Servier is licensed under a Creative Commons Attribution 3.0 Unported License (https://creativecommons.org/licenses/by/3.0/). Abstract Aims Sacubitril/valsartan (Sac/Val) is used for treatment of heart failure. The effect of Sac/Val on regional dysfunction
Einar Sjaastad Nordén+16 more
wiley +1 more source
Anomalous insertion of papillary muscle directly into anterior mitral leaflet in hypertrophic cardiomyopathy. Significance in producing left ventricular outflow obstruction. [PDF]
Heinrich G. Klues+2 more
openalex +1 more source
Takotsubo cardiomyopathy during armed conflict: A case series
ESC Heart Failure, Volume 12, Issue 2, Page 1494-1498, April 2025.
Sharon Bruoha+13 more
wiley +1 more source
Sequeira et al. reveal how the glucagon‐like peptide‐1 receptor agonist (GLP‐1‐RA) semaglutide restores cardiomyocyte function in rats subjected to a high‐fat/high‐fructose diet (HFD). Employing fluorescence‐ and patch‐clamp technology in isolated cardiac myocytes, they demonstrate that semaglutide reverses HFD‐induced activation of L‐type calcium ...
Vasco Sequeira+12 more
wiley +1 more source